Drugs like Zepbound and Wegovy are intended for people who are overweight. Some patients are using them after bariatric surgery to keep pounds from creeping back. Others may just want to lose a few ...

The GLP-1 market is a massive opportunity in healthcare, and many companies are vying for a piece of it.

Brooke Boyarsky Pratt, CEO, and Dr. Angela Fitch, chief medical officer, are both co-founders of knownwell. More than 12% of U.S. adults now take a GLP-1 medication, marking one of the ...

As GLP-1 medications reshape eating habits and private label innovation booms, beverages must deliver nutrient density, low sugar and smart positioning to stay competitive, according to Ravi Jhala, VP ...

GLP-1s are used for type 2 diabetes, as well as weight loss in people with obesity or overweight with a related health condition. Read on for everything you need to know about GLP-1s for weight loss, ...

While blockbuster drug innovations have changed health outcomes for decades, we’re now seeing signs that GLP-1 medications like Ozempic and Wegovy may be changing something broader: the consumer ...

Food brands are racing into GLP‑1-friendly ready meals, but are these products truly nutritious? We explore protein, fibre, fortification and the limits of processed options.

GLP-1 medications have reached a level of household penetration that food and beverage brands can no longer ignore, but the impact on grocery sales is unfolding more gradually than some might expect.

GLP-1 drugs have rapidly shifted from niche diabetes treatments to blockbuster weight loss injections, reshaping everything from cardiology guidelines to grocery bills. As prescriptions soar, a ...

More people are paying out-of-pocket for GLP-1 weight loss drugs — and more retailers are offering discounts on Zepbound, Ozempic, and Wegovy. Walmart will offer in-store pickup for Zepbound at ...

SAN DIEGO Dec 2 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab in 2020 launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients based on studies in humans, animals and ...

As doctors learn why GLP-1s don't work for about 50% of people, they are also learning more about the complex drivers of obesity. They foresee a future of personalized obesity medicine similar to the ...